84/100 A · Moderate risk
No major risk flags in public sources TraceComp due-diligence verdict — sanctions, screening, insolvency, control & financial signals combined.

✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)

ETHYPHARM

Active 5710 2120 Active for 48 years

5710 · RC 311999833 · Active since 1978

A

Overview

ETHYPHARM is a 5710 registered , France, since 1978. The company operates in the 2120 sector. With reported revenue of 134.7M EUR in 2024. Its TraceComp score of 84 (A) indicates solid fundamentals and low apparent risk. With 48 years of operations, the company has an established track record in its market.

Company Information

Registration Number
311999833
Legal Form
5710
Registered
1978-01-01

Financial Profile

Latest filed accounts: FY 2024

Revenue (2024) 134,730,737 EUR
Net Income 14,339,993 EUR
Total Assets 221,594,258 EUR
Altman Z 1.56 grey

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Officers & Management

6 officers/directors on file — names, roles, appointment & resignation dates.

NameRoleStatus
SEVERINE AUBRY Pharmacien Responsable Intérimaire Current
+ 5 more in the full report

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Public Contracts Won

Awarded 2 public-sector contracts totalling EUR 611,169,983 (DECP).

Which public buyers, contract titles, values and award dates.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Research Output

Active research organization. 120 publications · 6,194 citations · h-index 45 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Pharmacology, Toxicology and Pharmaceutics (36%) · Medicine (21%) · Agricultural and Biological Sciences (20%).

See full research profile — top researchers & publications →

Source: OpenAlex (CC0). Objective publication & citation counts.

Patent Portfolio

Active patent holder. 44 patents · 26 active · 44 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Profitable: positive net income in FY 2024

Data Sources & Freshness

Data sourced from: bulk register.